Organogenesis Holdings Inc.
ORGO
Rank in Stocks
#19347
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that... Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.
Share Price
$0.8101
Last synced: 2026-11-13
Market Cap
$104.50M
Change (1 day)
-16.05%
Change (1 year)
-84.18%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Organogenesis Holdings Inc. (ORGO)
Category
Healthcare
EPS for Organogenesis Holdings Inc. (ORGO)
EPS as of September 2026 TTM: $-1.18
According to Organogenesis Holdings Inc.'s latest financial reports, its current EPS (TTM) is $-1.18. At the end of 2025 the company had an EPS of $0.16, an increase over its 2024 EPS of $-0.01.
EPS history for Organogenesis Holdings Inc. from 2016 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.18 | -837.50% |
| 2025 | $0.16 | -2,353.52% |
| 2024 | $-0.01 | -118.83% |
| 2023 | $0.04 | -68.58% |
| 2022 | $0.12 | -83.56% |
| 2021 | $0.73 | 356.25% |
| 2020 | $0.16 | -136.36% |
| 2019 | $-0.44 | -53.19% |
| 2018 | $-0.94 | 2,765.85% |
| 2017 | $-0.03 | 34.98% |
| 2016 | $-0.02 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $6.03 | -611.01% |
DE
|
|
| $6.01 | -609.14% |
DE
|
|
| $1.53 | -229.91% |
JP
|
|
| $3.66 | -410.17% |
CH
|
|
| $0.45 | -138.14% |
IL
|
Questions about Organogenesis Holdings Inc.'s earnings per share (EPS)
What is Organogenesis Holdings Inc.'s earnings per share (EPS)?
Organogenesis Holdings Inc.'s earnings per share (EPS) over the last twelve months is $-1.18, as of Sep 2026.
What was Organogenesis Holdings Inc.'s earnings per share (EPS) in 2025?
In 2025, Organogenesis Holdings Inc.'s earnings per share (EPS) was $0.16, compared with $-0.01 in 2024.
How has Organogenesis Holdings Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Organogenesis Holdings Inc.'s earnings per share (EPS) went from $0.16 to $0.16, an average growth of 0.00% a year.
How does Organogenesis Holdings Inc.'s earnings per share (EPS) compare with similar companies?
Organogenesis Holdings Inc.'s earnings per share (EPS) ($-1.18) is lower than that of all 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.03.